Morphine Sulfate (Astramorph) Flashcards
Morphine Sulfate (Astramorph) Class
Opioid analgesic
Morphine Sulfate (Astramorph) Mechanism of Action
Alleviates pain through CNS action, suppresses fear and anxiety centers of the brain; depresses brain stem respiratory centers, increases peripheral venous capacitance and decreases venous return, decreases preload and afterload, which decreases myocardial oxygen demand.
Morphine Sulfate (Astramorph) Indications
Severe CHF, pulmonary edema, chest pain associated with an acute MI, analgesia for moderate to severe acute and chronic pain.
Morphine Sulfate (Astramorph) Contraindications
Head injury, exacerbated COPD, depressed respiratory drive, hypotension. Undiagnosed abdominal pain, decreases level of consciousness, suspected hypovolemia, patients who taken MAOIs in the last 14 days.
Morphine Sulfate (Astramorph) Adverse Reactions
Respiratory depression, hypotension, decreased level of consciousness, nausea, vomiting, bradycardia, tachycardia, syncope, facial flushing, euphoria, bronchospasm, and dry mouth.
Morphine Sulfate (Astramorph) Drug Interactions
Respiratory depression, hypotension, decreased level of consciousness, nausea, vomiting, bradycardia, tachycardia, syncope, facial flushing, euphoria, bronchospasm, and dry mouth.
Morphine Sulfate (Astramorph) Adult Dosage IV
Initial dose: 2 – 5 mg IV (over 1 – 5 minutes).
Repeat dose: 2 mg every 2 minutes titrated to effect.
Morphine Sulfate (Astramorph) Pediatric Dosage
0.1 – 0.2 mg/kg with a maximum dose of 5 mg, IV, IM, IO, or SC.
Morphine Sulfate (Astramorph) Onset
Immediate
Morphine Sulfate (Astramorph) Peak Effect
20 Minutes
Morphine Sulfate (Astramorph) Duration
2-7 Hours
Morphine Sulfate (Astramorph) Special Considerations
Use with caution in the geriatric population and those with COPD, asthma. Vagotonic effect in patients with an acute inferior MI, Naloxone should be readily available.
Morphine Sulfate (Astramorph) Adult Dose IM
5-15 mg IM based on patients weight
